Hidradenitis suppurativa is an inflammatory disease with difficult treatment. Currently, the anti-TNF alfa therapy, with monoclonal antibodies ('biological therapy'), has been shown as a new alternative. However, clinical trials assessing the efficacy of these drugs to treat hidradenitis suppurativa have not yet been published. A case in which the use of infliximab did not result in significant clinical improvement is described.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1590/s0365-05962009000600022 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!